. Second-gen take on Acomplia significantly trims body weight

Scientists working on a new obesity drug program at Denmark's 7TM Pharma say they've seen dramatic weight loss in rodents treated with a second-generation cannabinoid receptor blocker. And they say that they could be on to a successor to rimonabant, also known as Acomplia, which was yanked from the European market two years ago due to the troubling risk of psychiatric side effects.

This new drug, TM38837, is designed to work in human tissue and organs, but not the brain. This is where rimonabant ran into trouble--a number of patients on Acomplia complained of severe depression and suicidal thoughts. In fact, the experimental therapy looks just as effective as rimonabant in trimming weight. In mice, the drug was associated with a 22 percent to 26 percent drop in body weight compared with a placebo. Furthermore, drug-treated rats had 14 percent lower body weights than placebo-treated rats, PhysOrg reports.

• [07/10]媒體公布︰美國畢業生起薪最高5行業
• [07/11]屋主是否應該利用多餘的錢，每月多付一點房屋貸款，提前還清房屋貸款呢？
• [07/11]熱火隊已經可以提前宣布獲得冠軍了嗎？
• [07/12]美國加州舊金山市發生嚴重騷亂，轉貼
• [07/13]孩子哪些百分百來源於父母呢zt
• [07/14] . Second-gen take on Acomplia significantly trims body weight
• [07/14]中國銀髮浪潮到來
• [07/14]Best Places to Live in America2010 edition
• [07/15]美國百年房價分析
• [07/15]2010年百萬考生放棄高考選擇留學
• [07/15]完美生活=幸福婚姻+10萬年薪+百萬豪宅+高級跑車？
• [07/15]默默為美國幹活賣命的老印老中猛的從糊塗中醒悟過來zt
• [07/15]探討人老了退休以後得有多少錢才夠養老zt

• 查看：[TCM的.最新博文]
• 查看：[大家的.最新博文]
• 查看：[大家的.網路文摘]